SCHEDULE: Commodore Capital Discloses 5.1% Stake in Relmada Therapeutics

Commodore Capital LP, along with affiliated entities and individuals, has reported beneficial ownership of 5,505,527 shares, representing 5.1% of Relmada Therapeutics, Inc.'s common stock.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Michael Kramarz, and Robert Egen Atkinson have jointly filed a Schedule 13G.
• They collectively beneficially own 5,505,527 shares of Relmada Therapeutics, Inc. common stock.
• This holding represents 5.1% of the company's outstanding common stock.
• The reported shares include 1,295,000 directly owned shares and 4,210,527 shares issuable upon exercise of Pre-Funded Warrants.
• The filing date for this event is April 27, 2026.
• The reporting persons certify that these securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant investor confidence through a substantial stake acquisition, though the lack of operational details limits a more enthusiastic assessment.

Positives

• Significant stake of 5.1% acquired by Commodore Capital, indicating confidence in Relmada Therapeutics.
• The acquisition of shares through Pre-Funded Warrants suggests a strategic, long-term investment approach.

Negatives

• The filing does not contain information on financial performance or operational updates, limiting the assessment of the company's current health.

Risks

• The filing does not explicitly detail risks associated with the investment or the company's operations.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like Commodore Capital in biotechnology companies often signal a belief in the company's pipeline or market potential, especially in a sector driven by innovation and regulatory approvals.

Stakeholder Impact

• Shareholders may see the increased institutional interest as a positive signal, potentially leading to increased scrutiny and engagement.
• Management of Relmada Therapeutics will likely be aware of the significant stake held by Commodore Capital, potentially influencing strategic decisions and communications.

Next Steps

• Monitor future filings from Commodore Capital for any changes in their stake.
• Observe Relmada Therapeutics' operational and clinical developments that may influence the value of the Pre-Funded Warrants and the overall investment.

Key Dates

Recommendation

The filing indicates a significant investment by Commodore Capital, suggesting confidence in Relmada Therapeutics' future prospects. However, without operational or financial performance data from the company itself, a 'hold' recommendation is prudent, allowing for further evaluation of the company's underlying business before considering a buy or sell.

Keywords

Schedule 13G, Commodore Capital, Relmada Therapeutics, Beneficial Ownership, Pre-Funded Warrants, Investment Management, SEC Filing